EA
VRTX icon

Edge Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Edge Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		$1K Hold
6
– – ﹤0.01% 817
2018
Q1 		$0 Sell
6
-251
-98% -$41K ﹤0.01% 957
2017
Q4 		$38K Buy
257
+251
+4,183% +$37.2K ﹤0.01% 566
2017
Q3 		$0 Hold
6
– – ﹤0.01% 1004
2017
Q2 		$0 Buy
+6
New +$722 ﹤0.01% 1030

Other funds holding VRTX

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Edge Advisors's VRTX Position: Q2 2018 in Review

Edge Advisors held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2018 at 6 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #817.

Edge Advisors first reported a position in VRTX in Q2 2017 and has held it in 5 quarters since. The position peaked at $38K in Q4 2017. 689 funds tracked by Wall St. Rank hold VRTX as of Q2 2018.

  • Edge Advisors held 6 shares of Vertex Pharmaceuticals worth $1K as of Q2 2018.
  • Edge Advisors left its Vertex Pharmaceuticals share count unchanged in Q2 2018.
  • Vertex Pharmaceuticals made up ﹤0.01% of Edge Advisors's portfolio in Q2 2018, its #817 holding.
  • Edge Advisors first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 5 quarters since.
  • Edge Advisors's Vertex Pharmaceuticals position peaked at $38K in Q4 2017.
  • 689 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2018.

Based on Edge Advisors's 13F filing for Q2 2018, filed 14 Aug 2018.